Issue Date: June 28, 2010
Platinum Drugs Take Their Toll
Cisplatin’s approval in 1978 dramatically altered the prognosis for cancer patients. The cure rate for testicular cancer, for example, rose from about 10% to near 90%. Platinum compounds, including the follow-on drugs carboplatin and oxaliplatin, are now a cornerstone of solid-tumor chemotherapy. Alone or in combination with other agents, they are used to treat 40–80% of cancer patients.
Although platinum compounds were a leap forward, they are not perfect. The drugs are used to combat . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society